Gsa Capital Partners LLP Regenxbio Inc. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$16.46 - $19.99 $620,015 - $752,983	37,668 New	37,668 $620,000
Q2 2022 Aug 09, 2022	SELL	$19.35 - $35.04 $212,269 - $384,388	-10,970 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$24.62 - $34.31 $270,081 - $376,380	10,970 New	10,970 $364,000
Q4 2021 Feb 14, 2022	SELL	$30.19 - $40.28 $206,046 - $274,911	-6,825 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$29.09 - $45.68 $198,539 - $311,766	6,825 New	6,825 $286,000

Q1 2020 May 12, 2020	SELL	$21.5 - $54.2 $473,731 - $1.19 Million	-22,034 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$34.54 - $44.87 $761,054 - $988,665	22,034 New	22,034 $903,000
Q2 2019 Aug 06, 2019	SELL	$42.0 - $59.29 $754,572 - $1.07 Million	-17,966 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$40.82 - $62.45 $35,350 - $54,081	866 Added 5.06%	17,966 $1.03 Million
Q3 2018 Nov 13, 2018	SELL	$65.0 - $82.15 $51,220 - $64,734	-788 Reduced 4.41%	17,100 $1.29 Million
Q2 2018 Aug 09, 2018	BUY	$27.2 - $74.35 $486,553 - $1.33 Million	17,888 New	17,888 $1.28 Million

193

42.1M

80.6K

55.2K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $460M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.